Rationale and design of a randomized double‐blind event‐driven multicentre study comparing the efficacy and safety of oral rivaroxaban with placebo for reducing the risk of death myocardial infarction or stroke in subjects with heart failure and significant coronary artery disease following an exacerbation of heart failure: the COMMANDER HF trial

摘要

AimsThrombin is a critical element of crosstalk between pathways contributing to worsening of established heart failure (HF). The aim of this study is to explore the efficacy and safety of rivaroxaban 2.5 mg bid compared with placebo (with standard care) after an exacerbation of HF in patients with reduced ejection fraction (HF‐rEF) and documented coronary artery disease.